Omnicell Inc. (NASDAQ:OMCL) was down 2.5% during trading on Thursday . The company traded as low as $35.34 and last traded at $35.42, with a volume of 79,447 shares traded. The stock had previously closed at $36.32.

A number of equities research analysts have recently commented on OMCL shares. FBR & Co raised their price target on Omnicell from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Thursday, July 7th. Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a research report on Wednesday, June 29th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Omnicell currently has an average rating of “Buy” and an average price target of $37.25.

The company has a 50 day moving average price of $34.39 and a 200 day moving average price of $30.02. The firm has a market cap of $1.28 billion and a price-to-earnings ratio of 53.41.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, April 28th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.09. The firm had revenue of $171 million for the quarter, compared to the consensus estimate of $167.18 million. The firm’s revenue for the quarter was up 47.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.29 EPS. On average, equities research analysts forecast that Omnicell Inc. will post $1.56 EPS for the current year.

In other Omnicell news, EVP Robin Gene Seim sold 5,302 shares of the firm’s stock in a transaction that occurred on Wednesday, July 6th. The shares were sold at an average price of $34.75, for a total transaction of $184,244.50. Following the completion of the transaction, the executive vice president now owns 55,420 shares in the company, valued at approximately $1,925,845. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Jorge R. Taborga sold 23,827 shares of the firm’s stock in a transaction that occurred on Tuesday, April 26th. The stock was sold at an average price of $30.00, for a total transaction of $714,810.00. Following the sale, the vice president now directly owns 52,667 shares of the company’s stock, valued at approximately $1,580,010. The disclosure for this sale can be found here.

Other hedge funds recently made changes to their positions in the company. Edge Asset Management Inc. increased its stake in shares of Omnicell by 41.0% in the fourth quarter. Edge Asset Management Inc. now owns 378,276 shares of the company’s stock valued at $11,757,000 after buying an additional 110,035 shares during the period. Paradigm Capital Management Inc. NY increased its stake in shares of Omnicell by 32.4% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 412,600 shares of the company’s stock valued at $12,824,000 after buying an additional 100,900 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Omnicell by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,641,466 shares of the company’s stock valued at $51,017,000 after buying an additional 51,729 shares during the period. Mutual of America Capital Management LLC increased its stake in shares of Omnicell by 32.0% in the fourth quarter. Mutual of America Capital Management LLC now owns 152,422 shares of the company’s stock valued at $4,737,000 after buying an additional 36,911 shares during the period. Finally, PNC Financial Services Group Inc. increased its stake in shares of Omnicell by 10.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 93,675 shares of the company’s stock valued at $2,910,000 after buying an additional 9,066 shares during the period.

Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.